甲羟孕酮治疗去势抵抗型前列腺癌的疗效观察

目的：观察甲羟孕酮对于去势抵抗型前列腺癌（CRPC）的疗效及毒副反应。方法：观察62例 CRPC患者口服甲羟孕酮后，对比口服药物前后 PSA、生活质量 KPS 评分、血红蛋白、营养状况的变化，评价药物毒副反应。结果：62例患者经过口服甲羟孕酮后，PSA 下降的有效率为11．3％、稳定率达24．2％。KPS 评分、血红蛋白较前明显改善（P 值均＜0．05）。营养状况的改善率为64．5％、稳定率达30．6％。未发现 III －IV 级毒副反应，6例出现轻度低钠血症，5例出现轻度低钾血症，Ⅰ度下肢水肿较治疗前增加4例。结论：甲羟孕酮可延缓部分 CRPC 患者的 PSA 进展，改善晚期肿瘤患者的生活质量，毒副反应小。

Efficacy of medroxyprogesterone acetate treatment of castrate -resistant prostate cancer

Objective:To observe the efficacy and side effects of medroxyprogesterone in castrate -resistant pros-tate cancer (CRPC).Methods:PSA,KPS score,hemoglobin,nutritional status,and drug toxicity were evaluated in 62 CRPC patients before and after orally taking medroxyprogesterone.Results:After orally taking medroxyprogesterone, PSA decreased in 7 patients(11.3%),and remained stable in 15 patients(24.2%).KPS score and hemoglobin were improved significantly (P <0.05).The nutritional status were improved in 40 patients(64.5%),and remained stable in 19 patients(30.6%).No III -IV grade toxic and side effects were found.Six patients had mild hyponatremia,five patients had mild hypokalemia,four patients had Ⅰdegree lower limb edema after treatment.Conclusion:Medroxypro-gesterone may slow the progression of the PSA,improve the quality of life with few drug side effects in advanced CRPC patients.